Applied Therapeutics (NASDAQ:APLT) Announces Earnings Results, Misses Estimates By $0.12 EPS

Applied Therapeutics (NASDAQ:APLT) issued its quarterly earnings results on Monday. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.12), Bloomberg Earnings reports.

Shares of NASDAQ APLT opened at $9.36 on Wednesday. Applied Therapeutics has a one year low of $7.95 and a one year high of $11.20. The business’s 50-day simple moving average is $8.81.

In other Applied Therapeutics news, Director Joel S. Marcus acquired 150,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $1,500,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Shoshana Shendelman acquired 125,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were acquired at an average price of $10.00 per share, with a total value of $1,250,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,250,000 shares of company stock valued at $12,500,000 over the last 90 days.

A number of brokerages recently weighed in on APLT. Robert W. Baird assumed coverage on Applied Therapeutics in a research note on Monday, June 10th. They issued an “outperform” rating and a $24.00 price target on the stock. Citigroup assumed coverage on Applied Therapeutics in a research report on Monday, June 10th. They set a “buy” rating and a $29.00 price objective for the company. UBS Group assumed coverage on Applied Therapeutics in a research report on Monday, June 10th. They set a “buy” rating for the company. Finally, Cowen assumed coverage on Applied Therapeutics in a research report on Monday, June 10th. They set an “outperform” rating for the company.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.

Read More: Cash Flow

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.